Global Neuromyelitis Optica Drug Market Research Report 2026(Status and Outlook)

May 2026 | 147 pages | ID: N55B302E568EEN
Bosson Research

Abstracts

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.

The global Neuromyelitis Optica Drug market size was estimated at USD 49.8 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 3.00% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Neuromyelitis Optica Drug market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Neuromyelitis Optica Drug market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neuromyelitis Optica Drug market.

Global Neuromyelitis Optica Drug Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

• Pfizer
• Fresenius
• Teva
• Sandoz
• Intas
• Gyjtrs
• NANG KUANG
• Tianjin Kingyork
• Baxter
• CSL
• Grifols
• Octapharma
• CBOP

Market Segmentation (by Type)

• Glucocorticoids
• Immunotherapies
• Others

Market Segmentation (by Application)

• Acute Attack
• Remission Prophylactic Treatment

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Neuromyelitis Optica Drug Market

Overview of the regional outlook of the Neuromyelitis Optica Drug Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neuromyelitis Optica Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Neuromyelitis Optica Drug, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Neuromyelitis Optica Drug
1.2 Key Market Segments
  1.2.1 Neuromyelitis Optica Drug Segment by Type
  1.2.2 Neuromyelitis Optica Drug Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 NEUROMYELITIS OPTICA DRUG MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Neuromyelitis Optica Drug Market Size (M USD) Estimates and Forecasts (2020-2035)
  2.1.2 Global Neuromyelitis Optica Drug Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 NEUROMYELITIS OPTICA DRUG MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Neuromyelitis Optica Drug Product Life Cycle
3.3 Global Neuromyelitis Optica Drug Sales by Manufacturers (2020-2025)
3.4 Global Neuromyelitis Optica Drug Revenue Market Share by Manufacturers (2020-2025)
3.5 Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neuromyelitis Optica Drug Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Neuromyelitis Optica Drug Market Competitive Situation and Trends
  3.8.1 Neuromyelitis Optica Drug Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Neuromyelitis Optica Drug Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

4 NEUROMYELITIS OPTICA DRUG INDUSTRY CHAIN ANALYSIS

4.1 Neuromyelitis Optica Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF NEUROMYELITIS OPTICA DRUG MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Neuromyelitis Optica Drug Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 U.S. Tariff Policy – April 2025
  5.6.3 Global Trade Frictions and Their Impacts to Neuromyelitis Optica Drug Market
5.7 ESG Ratings of Leading Companies

6 NEUROMYELITIS OPTICA DRUG MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neuromyelitis Optica Drug Sales Market Share by Type (2020-2025)
6.3 Global Neuromyelitis Optica Drug Market Size by Type (2020-2025)
6.4 Global Neuromyelitis Optica Drug Price by Type (2020-2025)

7 NEUROMYELITIS OPTICA DRUG MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neuromyelitis Optica Drug Market Sales by Application (2020-2025)
7.3 Global Neuromyelitis Optica Drug Market Size (M USD) by Application (2020-2025)
7.4 Global Neuromyelitis Optica Drug Sales Growth Rate by Application (2020-2025)

8 NEUROMYELITIS OPTICA DRUG MARKET SALES BY REGION

8.1 Global Neuromyelitis Optica Drug Sales by Region
  8.1.1 Global Neuromyelitis Optica Drug Sales by Region
  8.1.2 Global Neuromyelitis Optica Drug Sales Market Share by Region
8.2 Global Neuromyelitis Optica Drug Market Size by Region
  8.2.1 Global Neuromyelitis Optica Drug Market Size by Region
  8.2.2 Global Neuromyelitis Optica Drug Market Size by Region
8.3 North America
  8.3.1 North America Neuromyelitis Optica Drug Sales by Country
  8.3.2 North America Neuromyelitis Optica Drug Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Neuromyelitis Optica Drug Sales by Country
  8.4.2 Europe Neuromyelitis Optica Drug Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific
  8.5.1 Asia Pacific Neuromyelitis Optica Drug Sales by Region
  8.5.2 Asia Pacific Neuromyelitis Optica Drug Market Size by Region
  8.5.3 China Market Overview
  8.5.4 Japan Market Overview
  8.5.5 South Korea Market Overview
  8.5.6 India Market Overview
  8.5.7 Southeast Asia Market Overview
8.6 South America
  8.6.1 South America Neuromyelitis Optica Drug Sales by Country
  8.6.2 South America Neuromyelitis Optica Drug Market Size by Country
  8.6.3 Brazil Market Overview
  8.6.4 Argentina Market Overview
  8.6.5 Columbia Market Overview
8.7 Middle East and Africa
  8.7.1 Middle East and Africa Neuromyelitis Optica Drug Sales by Region
  8.7.2 Middle East and Africa Neuromyelitis Optica Drug Market Size by Region
  8.7.3 Saudi Arabia Market Overview
  8.7.4 UAE Market Overview
  8.7.5 Egypt Market Overview
  8.7.6 Nigeria Market Overview
  8.7.7 South Africa Market Overview

9 NEUROMYELITIS OPTICA DRUG MARKET PRODUCTION BY REGION

9.1 Global Production of Neuromyelitis Optica Drug by Region(2020-2025)
9.2 Global Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2025)
9.3 Global Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neuromyelitis Optica Drug Production
  9.4.1 North America Neuromyelitis Optica Drug Production Growth Rate (2020-2025)
  9.4.2 North America Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neuromyelitis Optica Drug Production
  9.5.1 Europe Neuromyelitis Optica Drug Production Growth Rate (2020-2025)
  9.5.2 Europe Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neuromyelitis Optica Drug Production (2020-2025)
  9.6.1 Japan Neuromyelitis Optica Drug Production Growth Rate (2020-2025)
  9.6.2 Japan Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neuromyelitis Optica Drug Production (2020-2025)
  9.7.1 China Neuromyelitis Optica Drug Production Growth Rate (2020-2025)
  9.7.2 China Neuromyelitis Optica Drug Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Pfizer
  10.1.1 Pfizer Basic Information
  10.1.2 Pfizer Neuromyelitis Optica Drug Product Overview
  10.1.3 Pfizer Neuromyelitis Optica Drug Product Market Performance
  10.1.4 Pfizer Business Overview
  10.1.5 Pfizer SWOT Analysis
  10.1.6 Pfizer Recent Developments
10.2 Fresenius
  10.2.1 Fresenius Basic Information
  10.2.2 Fresenius Neuromyelitis Optica Drug Product Overview
  10.2.3 Fresenius Neuromyelitis Optica Drug Product Market Performance
  10.2.4 Fresenius Business Overview
  10.2.5 Fresenius SWOT Analysis
  10.2.6 Fresenius Recent Developments
10.3 Teva
  10.3.1 Teva Basic Information
  10.3.2 Teva Neuromyelitis Optica Drug Product Overview
  10.3.3 Teva Neuromyelitis Optica Drug Product Market Performance
  10.3.4 Teva Business Overview
  10.3.5 Teva SWOT Analysis
  10.3.6 Teva Recent Developments
10.4 Sandoz
  10.4.1 Sandoz Basic Information
  10.4.2 Sandoz Neuromyelitis Optica Drug Product Overview
  10.4.3 Sandoz Neuromyelitis Optica Drug Product Market Performance
  10.4.4 Sandoz Business Overview
  10.4.5 Sandoz Recent Developments
10.5 Intas
  10.5.1 Intas Basic Information
  10.5.2 Intas Neuromyelitis Optica Drug Product Overview
  10.5.3 Intas Neuromyelitis Optica Drug Product Market Performance
  10.5.4 Intas Business Overview
  10.5.5 Intas Recent Developments
10.6 Gyjtrs
  10.6.1 Gyjtrs Basic Information
  10.6.2 Gyjtrs Neuromyelitis Optica Drug Product Overview
  10.6.3 Gyjtrs Neuromyelitis Optica Drug Product Market Performance
  10.6.4 Gyjtrs Business Overview
  10.6.5 Gyjtrs Recent Developments
10.7 NANG KUANG
  10.7.1 NANG KUANG Basic Information
  10.7.2 NANG KUANG Neuromyelitis Optica Drug Product Overview
  10.7.3 NANG KUANG Neuromyelitis Optica Drug Product Market Performance
  10.7.4 NANG KUANG Business Overview
  10.7.5 NANG KUANG Recent Developments
10.8 Tianjin Kingyork
  10.8.1 Tianjin Kingyork Basic Information
  10.8.2 Tianjin Kingyork Neuromyelitis Optica Drug Product Overview
  10.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Product Market Performance
  10.8.4 Tianjin Kingyork Business Overview
  10.8.5 Tianjin Kingyork Recent Developments
10.9 Baxter
  10.9.1 Baxter Basic Information
  10.9.2 Baxter Neuromyelitis Optica Drug Product Overview
  10.9.3 Baxter Neuromyelitis Optica Drug Product Market Performance
  10.9.4 Baxter Business Overview
  10.9.5 Baxter Recent Developments
10.10 CSL
  10.10.1 CSL Basic Information
  10.10.2 CSL Neuromyelitis Optica Drug Product Overview
  10.10.3 CSL Neuromyelitis Optica Drug Product Market Performance
  10.10.4 CSL Business Overview
  10.10.5 CSL Recent Developments
10.11 Grifols
  10.11.1 Grifols Basic Information
  10.11.2 Grifols Neuromyelitis Optica Drug Product Overview
  10.11.3 Grifols Neuromyelitis Optica Drug Product Market Performance
  10.11.4 Grifols Business Overview
  10.11.5 Grifols Recent Developments
10.12 Octapharma
  10.12.1 Octapharma Basic Information
  10.12.2 Octapharma Neuromyelitis Optica Drug Product Overview
  10.12.3 Octapharma Neuromyelitis Optica Drug Product Market Performance
  10.12.4 Octapharma Business Overview
  10.12.5 Octapharma Recent Developments
10.13 CBOP
  10.13.1 CBOP Basic Information
  10.13.2 CBOP Neuromyelitis Optica Drug Product Overview
  10.13.3 CBOP Neuromyelitis Optica Drug Product Market Performance
  10.13.4 CBOP Business Overview
  10.13.5 CBOP Recent Developments

11 NEUROMYELITIS OPTICA DRUG MARKET FORECAST BY REGION

11.1 Global Neuromyelitis Optica Drug Market Size Forecast
11.2 Global Neuromyelitis Optica Drug Market Forecast by Region
  11.2.1 North America Market Size Forecast by Country
  11.2.2 Europe Neuromyelitis Optica Drug Market Size Forecast by Country
  11.2.3 Asia Pacific Neuromyelitis Optica Drug Market Size Forecast by Region
  11.2.4 South America Neuromyelitis Optica Drug Market Size Forecast by Country
  11.2.5 Middle East and Africa Forecasted Sales of Neuromyelitis Optica Drug by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Neuromyelitis Optica Drug Market Forecast by Type (2026-2035)
  12.1.1 Global Forecasted Sales of Neuromyelitis Optica Drug by Type (2026-2035)
  12.1.2 Global Neuromyelitis Optica Drug Market Size Forecast by Type (2026-2035)
  12.1.3 Global Forecasted Price of Neuromyelitis Optica Drug by Type (2026-2035)
12.2 Global Neuromyelitis Optica Drug Market Forecast by Application (2026-2035)
  12.2.1 Global Neuromyelitis Optica Drug Sales (K MT) Forecast by Application
  12.2.2 Global Neuromyelitis Optica Drug Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neuromyelitis Optica Drug Market Size by Type (M USD)
Table 4. Global Neuromyelitis Optica Drug Market Size by Application
Table 5. Neuromyelitis Optica Drug Market Size Comparison by Region (M USD)
Table 6. Global Neuromyelitis Optica Drug Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Neuromyelitis Optica Drug Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Neuromyelitis Optica Drug Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Neuromyelitis Optica Drug Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2025)
Table 11. Global Market Neuromyelitis Optica Drug Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Neuromyelitis Optica Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neuromyelitis Optica Drug Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Neuromyelitis Optica Drug Sales by Type (K MT)
Table 27. Global Neuromyelitis Optica Drug Market Size by Type (M USD)
Table 28. Global Neuromyelitis Optica Drug Sales (K MT) by Type (2020-2025)
Table 29. Global Neuromyelitis Optica Drug Sales Market Share by Type (2020-2025)
Table 30. Global Neuromyelitis Optica Drug Market Size (M USD) by Type (2020-2025)
Table 31. Global Neuromyelitis Optica Drug Market Share by Type (2020-2025)
Table 32. Global Neuromyelitis Optica Drug Price (USD/KG) by Type (2020-2025)
Table 33. Global Neuromyelitis Optica Drug Sales (K MT) by Application
Table 34. Global Neuromyelitis Optica Drug Market Size by Application
Table 35. Global Neuromyelitis Optica Drug Sales by Application (2020-2025) & (K MT)
Table 36. Global Neuromyelitis Optica Drug Sales Market Share by Application (2020-2025)
Table 37. Global Neuromyelitis Optica Drug Market Size by Application (2020-2025) & (M USD)
Table 38. Global Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Table 39. Global Neuromyelitis Optica Drug Sales Growth Rate by Application (2020-2025)
Table 40. Global Neuromyelitis Optica Drug Sales by Region (2020-2025) & (K MT)
Table 41. Global Neuromyelitis Optica Drug Sales Market Share by Region (2020-2025)
Table 42. Global Neuromyelitis Optica Drug Market Size by Region (2020-2025) & (M USD)
Table 43. Global Neuromyelitis Optica Drug Market Size by Region (2020-2025)
Table 44. North America Neuromyelitis Optica Drug Sales by Country (2020-2025) & (K MT)
Table 45. North America Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Neuromyelitis Optica Drug Sales by Country (2020-2025) & (K MT)
Table 47. Europe Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Neuromyelitis Optica Drug Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Neuromyelitis Optica Drug Market Size by Region (2020-2025) & (M USD)
Table 50. South America Neuromyelitis Optica Drug Sales by Country (2020-2025) & (K MT)
Table 51. South America Neuromyelitis Optica Drug Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Neuromyelitis Optica Drug Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Neuromyelitis Optica Drug Market Size by Region (2020-2025) & (M USD)
Table 54. Global Neuromyelitis Optica Drug Production (K MT) by Region(2020-2025)
Table 55. Global Neuromyelitis Optica Drug Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2025)
Table 57. Global Neuromyelitis Optica Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Neuromyelitis Optica Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Neuromyelitis Optica Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Neuromyelitis Optica Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Neuromyelitis Optica Drug Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Pfizer Basic Information
Table 63. Pfizer Neuromyelitis Optica Drug Product Overview
Table 64. Pfizer Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Pfizer Business Overview
Table 66. Pfizer SWOT Analysis
Table 67. Pfizer Recent Developments
Table 68. Fresenius Basic Information
Table 69. Fresenius Neuromyelitis Optica Drug Product Overview
Table 70. Fresenius Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Fresenius Business Overview
Table 72. Fresenius SWOT Analysis
Table 73. Fresenius Recent Developments
Table 74. Teva Basic Information
Table 75. Teva Neuromyelitis Optica Drug Product Overview
Table 76. Teva Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Teva Business Overview
Table 78. Teva SWOT Analysis
Table 79. Teva Recent Developments
Table 80. Sandoz Basic Information
Table 81. Sandoz Neuromyelitis Optica Drug Product Overview
Table 82. Sandoz Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Sandoz Business Overview
Table 84. Sandoz Recent Developments
Table 85. Intas Basic Information
Table 86. Intas Neuromyelitis Optica Drug Product Overview
Table 87. Intas Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Intas Business Overview
Table 89. Intas Recent Developments
Table 90. Gyjtrs Basic Information
Table 91. Gyjtrs Neuromyelitis Optica Drug Product Overview
Table 92. Gyjtrs Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Gyjtrs Business Overview
Table 94. Gyjtrs Recent Developments
Table 95. NANG KUANG Basic Information
Table 96. NANG KUANG Neuromyelitis Optica Drug Product Overview
Table 97. NANG KUANG Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. NANG KUANG Business Overview
Table 99. NANG KUANG Recent Developments
Table 100. Tianjin Kingyork Basic Information
Table 101. Tianjin Kingyork Neuromyelitis Optica Drug Product Overview
Table 102. Tianjin Kingyork Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Tianjin Kingyork Business Overview
Table 104. Tianjin Kingyork Recent Developments
Table 105. Baxter Basic Information
Table 106. Baxter Neuromyelitis Optica Drug Product Overview
Table 107. Baxter Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Baxter Business Overview
Table 109. Baxter Recent Developments
Table 110. CSL Basic Information
Table 111. CSL Neuromyelitis Optica Drug Product Overview
Table 112. CSL Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. CSL Business Overview
Table 114. CSL Recent Developments
Table 115. Grifols Basic Information
Table 116. Grifols Neuromyelitis Optica Drug Product Overview
Table 117. Grifols Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Grifols Business Overview
Table 119. Grifols Recent Developments
Table 120. Octapharma Basic Information
Table 121. Octapharma Neuromyelitis Optica Drug Product Overview
Table 122. Octapharma Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Octapharma Business Overview
Table 124. Octapharma Recent Developments
Table 125. CBOP Basic Information
Table 126. CBOP Neuromyelitis Optica Drug Product Overview
Table 127. CBOP Neuromyelitis Optica Drug Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. CBOP Business Overview
Table 129. CBOP Recent Developments
Table 130. Global Neuromyelitis Optica Drug Sales Forecast by Region (2026-2035) & (K MT)
Table 131. Global Neuromyelitis Optica Drug Market Size Forecast by Region (2026-2035) & (M USD)
Table 132. North America Neuromyelitis Optica Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 133. North America Neuromyelitis Optica Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 134. Europe Neuromyelitis Optica Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 135. Europe Neuromyelitis Optica Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 136. Asia Pacific Neuromyelitis Optica Drug Sales Forecast by Region (2026-2035) & (K MT)
Table 137. Asia Pacific Neuromyelitis Optica Drug Market Size Forecast by Region (2026-2035) & (M USD)
Table 138. South America Neuromyelitis Optica Drug Sales Forecast by Country (2026-2035) & (K MT)
Table 139. South America Neuromyelitis Optica Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 140. Middle East and Africa Neuromyelitis Optica Drug Sales Forecast by Country (2026-2035) & (Units)
Table 141. Middle East and Africa Neuromyelitis Optica Drug Market Size Forecast by Country (2026-2035) & (M USD)
Table 142. Global Neuromyelitis Optica Drug Sales Forecast by Type (2026-2035) & (K MT)
Table 143. Global Neuromyelitis Optica Drug Market Size Forecast by Type (2026-2035) & (M USD)
Table 144. Global Neuromyelitis Optica Drug Price Forecast by Type (2026-2035) & (USD/KG)
Table 145. Global Neuromyelitis Optica Drug Sales (K MT) Forecast by Application (2026-2035)
Table 146. Global Neuromyelitis Optica Drug Market Size Forecast by Application (2026-2035) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Neuromyelitis Optica Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neuromyelitis Optica Drug Market Size (M USD), 2025-2035
Figure 5. Global Neuromyelitis Optica Drug Market Size (M USD) (2020-2035)
Figure 6. Global Neuromyelitis Optica Drug Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neuromyelitis Optica Drug Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neuromyelitis Optica Drug Product Life Cycle
Figure 13. Neuromyelitis Optica Drug Sales Share by Manufacturers in 2025
Figure 14. Global Neuromyelitis Optica Drug Revenue Share by Manufacturers in 2025
Figure 15. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Neuromyelitis Optica Drug Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neuromyelitis Optica Drug Revenue in 2025
Figure 18. Industry Chain Map of Neuromyelitis Optica Drug
Figure 19. Global Neuromyelitis Optica Drug Market PEST Analysis
Figure 20. Global Neuromyelitis Optica Drug Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neuromyelitis Optica Drug Market Share by Type
Figure 27. Sales Market Share of Neuromyelitis Optica Drug by Type (2020-2025)
Figure 28. Sales Market Share of Neuromyelitis Optica Drug by Type in 2025
Figure 29. Market Share of Neuromyelitis Optica Drug by Type (2020-2025)
Figure 30. Market Share of Neuromyelitis Optica Drug by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neuromyelitis Optica Drug Market Share by Application
Figure 33. Global Neuromyelitis Optica Drug Sales Market Share by Application (2020-2025)
Figure 34. Global Neuromyelitis Optica Drug Sales Market Share by Application in 2025
Figure 35. Global Neuromyelitis Optica Drug Market Share by Application (2020-2025)
Figure 36. Global Neuromyelitis Optica Drug Market Share by Application in 2025
Figure 37. Global Neuromyelitis Optica Drug Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neuromyelitis Optica Drug Sales Market Share by Region (2020-2025)
Figure 39. Global Neuromyelitis Optica Drug Market Size by Region (2020-2025)
Figure 40. North America Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neuromyelitis Optica Drug Sales Market Share by Country in 2024
Figure 43. North America Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neuromyelitis Optica Drug Market Size by Country in 2024
Figure 45. U.S. Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neuromyelitis Optica Drug Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neuromyelitis Optica Drug Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neuromyelitis Optica Drug Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neuromyelitis Optica Drug Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neuromyelitis Optica Drug Sales Market Share by Country in 2024
Figure 53. Europe Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neuromyelitis Optica Drug Market Size by Country in 2024
Figure 55. Germany Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neuromyelitis Optica Drug Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neuromyelitis Optica Drug Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neuromyelitis Optica Drug Market Size by Region in 2024
Figure 68. China Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neuromyelitis Optica Drug Sales and Growth Rate (K MT)
Figure 79. South America Neuromyelitis Optica Drug Sales Market Share by Country in 2024
Figure 80. South America Neuromyelitis Optica Drug Market Size and Growth Rate (M USD)
Figure 81. South America Neuromyelitis Optica Drug Market Size by Country in 2024
Figure 82. Brazil Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neuromyelitis Optica Drug Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neuromyelitis Optica Drug Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neuromyelitis Optica Drug Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neuromyelitis Optica Drug Market Size by Region in 2024
Figure 92. Saudi Arabia Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neuromyelitis Optica Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neuromyelitis Optica Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neuromyelitis Optica Drug Production Market Share by Region (2020-2025)
Figure 103. North America Neuromyelitis Optica Drug Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neuromyelitis Optica Drug Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neuromyelitis Optica Drug Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neuromyelitis Optica Drug Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neuromyelitis Optica Drug Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Neuromyelitis Optica Drug Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Neuromyelitis Optica Drug Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Neuromyelitis Optica Drug Market Share Forecast by Type (2026-2035)
Figure 111. Global Neuromyelitis Optica Drug Sales Forecast by Application (2026-2035)
Figure 112. Global Neuromyelitis Optica Drug Market Share Forecast by Application (2026-2035)